<p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p
The model for end-stage liver disease (MELD) has replaced the role of the Child–Turcotte–Pugh system...
A notable threshold can be seen at the DAA 20% and SA/MAT 20% scale. There the inclusion of even low...
<p>Changes in laboratory results under DAA therapy and during follow-up in patients on the liver tra...
Few data are available on the virological and clinical outcomes of advanced liver disease patients r...
BackgroundFew data are available on the virological and clinical outcomes of advanced liver disease ...
Background & Aims: HCV-infected patients with cirrhosis achieve high sustained virological response ...
<p>The best-fit (solid line) and 95% CIs (dashed lines) of Eq (<a href="http://www.ploscompbiol.org/...
Background and aims: Large scale, real life data on the long term course of liver disease after HCV ...
<p><b>(A) Changes of MELD scores in patients on the liver transplant waiting list.</b> Changes did n...
Logistic regression analyses of hepatic decompensation in patients with liver cirrhosis.</p
Management of decompensated cirrhosis is currently geared towards the treatment of complications onc...
The model for end-stage liver disease (MELD) has replaced the role of the Child–Turcotte–Pugh system...
A notable threshold can be seen at the DAA 20% and SA/MAT 20% scale. There the inclusion of even low...
<p>Changes in laboratory results under DAA therapy and during follow-up in patients on the liver tra...
Few data are available on the virological and clinical outcomes of advanced liver disease patients r...
BackgroundFew data are available on the virological and clinical outcomes of advanced liver disease ...
Background & Aims: HCV-infected patients with cirrhosis achieve high sustained virological response ...
<p>The best-fit (solid line) and 95% CIs (dashed lines) of Eq (<a href="http://www.ploscompbiol.org/...
Background and aims: Large scale, real life data on the long term course of liver disease after HCV ...
<p><b>(A) Changes of MELD scores in patients on the liver transplant waiting list.</b> Changes did n...
Logistic regression analyses of hepatic decompensation in patients with liver cirrhosis.</p
Management of decompensated cirrhosis is currently geared towards the treatment of complications onc...
The model for end-stage liver disease (MELD) has replaced the role of the Child–Turcotte–Pugh system...
A notable threshold can be seen at the DAA 20% and SA/MAT 20% scale. There the inclusion of even low...
<p>Changes in laboratory results under DAA therapy and during follow-up in patients on the liver tra...